Trial Profile
An impact of cachexia on the survival of metastatic renal cell carcinoma (mRCC) patients receiving first-line sunitinib treatment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 09 Jun 2016 New trial record
- 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association